Palbociclib (PAL) plus letrozole (L) as first-line (1) therapy (tx) in estrogen receptor-positive (ER plus )/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Efficacy and safety across patient (pt) subgroups.

被引：6
作者：
Finn, Richard S.
Dieras, Veronique
Rugo, Hope S.
Joy, Anil A.
Moulder, Stacy L.
Walshe, Janice Maria
Mukai, Hirofumi
Shparyk, Yaroslav V.
Park, In Hae
Mori, Ave
Lu, Dongrui
Gauthier, Eric Roland
Gelmon, Karen A.
机构：
[1] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[2] Inst Curie, Paris, France
[3] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
[4] Cross Canc Inst, Edmonton, AB, Canada
[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[6] CCRT, Dublin, Ireland
[7] Natl Canc Ctr Hosp East, Chiba, Japan
[8] Lviv State Oncol Reg Med & Diagnost Ctr, Lvov, Ukraine
[9] Natl Canc Ctr, Ctr Breast Canc, Goyangsi, South Korea
[10] Pfizer Srl, Milan, Italy
[11] Pfizer Inc, La Jolla, CA USA
[12] British Columbia Canc Agcy, Vancouver, BC, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.1039
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1039
引用
收藏
页数：6
相关论文
共 50 条
[31]   Everolimus (EVE) plus letrozole (LET) in patients (pts) with estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Progression-free survival (PFS) subgroup analyses in BOLERO-4 [J].
Bachelot, T. ;
Royce, M. ;
Villanueva, C. ;
Melo Cruz, F. ;
Hegg, R. ;
Falkson, C. ;
Jeong, J. ;
Srimuninnimit, V. ;
Arce, C. H. ;
Ridolfi, A. ;
Lin, C. ;
Gradishar, W. ;
Ozguroglu, M. ;
Cardoso, F. ;
Azevedo, S. .
ANNALS OF ONCOLOGY, 2017, 28
[32]   ECONOMIC ANALYSIS OF COMBINATION THERAPY WITH ALPELISIB AND FULVESTRANT FOR TREATMENT OF HORMONE RECEPTOR-POSITIVE (HR plus ) AND HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-) ADVANCED BREAST CANCER [J].
Delevry, D. ;
Le, Q. A. .
VALUE IN HEALTH, 2020, 23 :S32-S33
[33]   Impact of palbociclib combinations on treatment of advanced estrogen receptor-positive/human epidermal growth factor 2-negative breast cancer [J].
Boer, Katalin .
ONCOTARGETS AND THERAPY, 2016, 9 :6119-6125
[34]   CompLEEment-1: Phase 3b study of ribociclib plus letrozole for the treatment of hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) in patients with no prior endocrine therapy (ET) for ABC [J].
De Laurentiis, M. ;
Martin Jimenez, M. ;
Ring, A. ;
Cottu, P. ;
Zhou, K. ;
Wu, J. ;
Zarate, J. P. ;
Zamagni, C. .
ANNALS OF ONCOLOGY, 2017, 28
[35]   Randomized Phase III Study of Amcenestrant Plus Palbociclib Versus Letrozole Plus Palbociclib in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Primary Results From AMEERA-5 [J].
Cortes, Javier ;
Hurvitz, Sara A. ;
O'Shaughnessy, Joyce ;
Delaloge, Suzette ;
Iwata, Hiroji ;
Rugo, Hope S. ;
Neven, Patrick ;
Kanagavel, Dheepak ;
Cohen, Patrick ;
Paux, Gautier ;
Cartot-Cotton, Sylvaine ;
Stefanova-Urena, Maya ;
Deyme, Laure ;
Aouni, Jihane ;
Sebastien, Bernard ;
Bardia, Aditya .
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (22) :2680-2690
[36]   Ribociclib (RIB) plus fulvestrant (FUL) in hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-3 biomarker analyses [J].
Neven, P. ;
Petrakova, K. ;
Bianchi, G. V. ;
Merino, L. De la Cruz ;
Jerusalem, G. ;
Beck, J. T. ;
Sonke, G. S. ;
Chia, S. ;
Brucker, S. ;
Wang, Y. ;
He, W. ;
Lorenc, K. Rodriguez ;
Su, F. ;
Im, S-A. .
ANNALS OF ONCOLOGY, 2018, 29 :113-+
[37]   Everolimus (EVE) plus endocrine therapy in patients with estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (BC): First-and second-line data from the BOLERO-4 study. [J].
Cardoso, Fatima ;
Villanueva, Cristian ;
Royce, Melanie ;
Cruz, Felipe ;
Debled, Marc ;
Hegg, Roberto ;
Toyama, Tatsuya ;
Falkson, Carla Isadora ;
Jeong, Joon ;
Srimuninnimit, Vichien ;
Ozguroglu, Mustafa ;
Gradishar, William John ;
Azevedo, Sergio J. ;
Arce, Christina H. ;
Ridolfi, Antonia ;
Lin, Chinjune ;
Bachelot, Thomas Denis .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[38]   Ribociclib plus letrozole in patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Expanded safety analysis of the phase IIIb CompLEEment-1 trial [J].
Lu, Janice ;
Cottu, Paul ;
Martin, Miguel ;
Zamagni, Claudio ;
Prat, Aleix ;
Chia, Stephen ;
Jerusalem, Guy ;
Rajappa, Senthil ;
Timcheva, Constanta ;
Zhukova, Lyudmila ;
Zhou, Katie ;
Wu, Jiwen ;
Menon-Singh, Lakshmi ;
De Laurentiis, Michelino .
CANCER RESEARCH, 2021, 81 (04)
[39]   BUDGET IMPACT OF RIBOCICLIB PLUS LETROZOLE FOR THE TREATMENT OF POST-MENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE (HR plus ), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-) ADVANCED OR METASTATIC BREAST CANCER IN DENMARK [J].
Moller, A. H. ;
Oddershede, L. .
VALUE IN HEALTH, 2019, 22 :S483-S483
[40]   ZN-c5, an oral selective estrogen receptor degrader (SERD), in women with advanced estrogen receptor-positive (ER plus )/human epidermal growth factor receptor 2 negative (HER2-) breast cancer [J].
Kalinksy, Kevin ;
Abramson, Vandana ;
Chalasani, Pavani ;
Linden, Hannah M. ;
Alidzanovic, Jasmina ;
Layman, Rachel M. ;
Vranjes, Zivko ;
Nangia, Julie R. ;
Crew, Katherine D. ;
Andric, Zoran ;
Milovic-Kovacevic, Marijana ;
Trifunovic, Jasna ;
Suarez, Jose ;
Suster, Matt ;
Ptaszynski, Mieke ;
Mortimer, Joanne .
CANCER RESEARCH, 2022, 82 (04)
12345